In:
Frontiers in Immunology, Frontiers Media SA, Vol. 13 ( 2022-12-9)
Abstract:
Osteosarcoma (OS) is a highly aggressive bone malignancy with a poor prognosis, mainly in children and adolescents. Immunogenic cell death (ICD) is classified as a type of programmed cell death associated with the tumor immune microenvironment, prognosis, and immunotherapy. However, the feature of the ICD molecular subtype and the related tumor microenvironment (TME) and immune cell infiltration has not been carefully investigated in OS. Methods The ICD-related genes were extracted from previous studies, and the RNA expression profiles and corresponding data of OS were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus database. The ICD-related molecular subtypes were classed by the "ConsensusclusterPlus" package and the construction of ICD-related signatures through univariate regression analysis. ROC curves, independent analysis, and internal validation were used to evaluate signature performance. Moreover, a series of bioinformatic analyses were used for Immunotherapy efficacy, tumor immune microenvironments, and chemotherapeutic drug sensitivity between the high- and low-risk groups. Results Herein, we identified two ICD-related subtypes and found significant heterogeneity in clinical prognosis, TME, and immune response signaling among distinct ICD subtypes. Subsequently, a novel ICD-related prognostic signature was developed to determine its predictive performance in OS. Also, a highly accurate nomogram was then constructed to improve the clinical applicability of the novel ICD-related signature. Furthermore, we observed significant correlations between ICD risk score and TME, immunotherapy response, and chemotherapeutic drug sensitivity. Notably, the in vitro experiments further verified that high GALNT14 expression is closely associated with poor prognosis and malignant progress of OS. Discussion Hence, we identified and validated that the novel ICD-related signature could serve as a promising biomarker for the OS's prognosis, chemotherapy, and immunotherapy response prediction, providing guidance for personalized and accurate immunotherapy strategies for OS.
Type of Medium:
Online Resource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2022.1071636
DOI:
10.3389/fimmu.2022.1071636.s001
DOI:
10.3389/fimmu.2022.1071636.s002
DOI:
10.3389/fimmu.2022.1071636.s003
DOI:
10.3389/fimmu.2022.1071636.s004
DOI:
10.3389/fimmu.2022.1071636.s005
DOI:
10.3389/fimmu.2022.1071636.s006
DOI:
10.3389/fimmu.2022.1071636.s007
DOI:
10.3389/fimmu.2022.1071636.s008
DOI:
10.3389/fimmu.2022.1071636.s009
DOI:
10.3389/fimmu.2022.1071636.s010
DOI:
10.3389/fimmu.2022.1071636.s011
DOI:
10.3389/fimmu.2022.1071636.s012
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2606827-8
Permalink